Growth momentum Leverage BMS UK & Ireland's expanding portfolio and recently reported strong quarterly revenues driven by newer products such as Breyanzi, Opdualag, and Camzyos to position cross-sell opportunities in oncology, immunology, and cardiovascular care across regional markets.

Strategic partnerships Highlight opportunities to align with BMS's external innovation strategy and R&D partnerships to co-develop or co-commercialize therapies, potentially tapping into early access programs and regional clinical trials in key disease areas.

Digital maturity Target IT and security stakeholders leveraging BMS’s tech stack including Azure Monitor, SailPoint and other tools to offer scalable cloud, data analytics, identity and governance solutions that support regulated pharma operations and patient data protection.

Global-UK focus Capitalize on UK & Ireland footprint with a structured approach to supply chain resilience, manufacturing efficiency, and sustainable practices, offering services or solutions that enhance cost efficiency and regulatory compliance in the region.

Financial health Position value-driven partnerships around high-margin therapeutic areas and late-stage pipelines, recognizing the company’s revenue growth signals and potential for increased IT, clinical, and manufacturing outsourcing or vendor consolidation.